Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Akili, Inc. (AKLI)
Company Research
Source: Yahoo! Finance
Reports fourth quarter 2023 total revenues of $749 thousand, representing 7% growth over the third quarter of 2023, and positive gross margins of 66%, representing a 6 percentage point increase over the third quarter of 2023 Akili partner Shionogi releases positive Phase 3 trial results and submits Akili's digital therapeutic SDT-001 for marketing approval in Japan Company lowers FY 2024 non-GAAP total operating expense guidance to between $38 million and $43 million and reaffirms gross margins guidance of 60-70% by late 2025; ends FY 2023 with $75.2 million in cash and cash equivalents and reaffirms cash runway into 2H 2025 BOSTON, February 29, 2024 BUSINESS WIRE )--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2023, and provided an update on business progress. "We continue to see clear demand for our innovative, digital therapeutics, particularly amidst the ongoing mental
Show less
Read more
Impact Snapshot
Event Time:
AKLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKLI alerts
High impacting Akili, Inc. news events
Weekly update
A roundup of the hottest topics
AKLI
News
- Neurodivergence In The 21st Century: How Technology Supports Children's Potential [Forbes]Forbes
- Akili Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateBusiness Wire
- PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan [Yahoo! Finance]Yahoo! Finance
- Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in Japan [Yahoo! Finance]Yahoo! Finance
AKLI
Sec Filings
- 4/23/24 - Form 8-K
- 3/12/24 - Form 4
- 3/12/24 - Form 4
- AKLI's page on the SEC website